News
Public · Published
Argus Research maintains Amgen at Buy, raises price target to $515 from $460
Argus Research kept its Buy rating on Amgen and raised its price target to $515 from $460. The new target is a 12.0% increase and implies 10.0% upside from Amgen's Nov. 11 closing price of $468.11.
Published:
Updated:
What happened
Argus Research kept its Buy rating on Amgen and raised its price target to $515 from $460. The new target is a 12.0% increase and implies 10.0% upside from Amgen’s Nov. 11 closing price of $468.11.
Confirmed
Global impact / market context
The higher target signals that Argus sees more potential value in Amgen shares, but it is an analyst view, not a company forecast or guaranteed return. If investors act on it, buying could support the share price; the article does not report a market reaction.
Analyst inference
Recent analyst views are mixed: five notes from the past 30 days set targets between $435 and $530, with ratings ranging from Hold to Buy. That spread shows differing expectations and places Argus’s $515 target near the upper end.
Confirmed
What to watch
- Compare future analyst ratings and targets with Argus’s $515 figure; changes in the range of views could alter investor expectations for Amgen shares. Analyst inference
- Watch whether Amgen’s share price moves toward or away from the target’s implied 10.0% upside from the Nov. 11 close; no response is reported here. Analyst inference
- The article gives no reason for Argus’s higher target, so any later explanation linking it to Amgen’s revenue, costs, or business outlook would be new information. Analyst inference
Evidence
- Original source link unavailable